Table 1 Characteristics of study participants in adulthood and perinatal data
From: Large airway T cells in adults with former bronchopulmonary dysplasia
Full term-birth | Preterm-birth | |||
|---|---|---|---|---|
Healthy | Asthma | Preterm | BPD | |
Adulthood, n | 23 | 22 | 20 | 23 |
Age | 20.4 (19.1–20.8) | 20.3 (19.5–21.9) | 19.1 (18.9–19.4)* | 19.6 (19.0-19.8)* |
BMI | 21.7 (20.5–23.6) | 22.7 (20.6–25.7) | 20.9 (19.4–23.7) | 21.9 (19.4–24.1) |
Gender (males) | 11 (47.8) | 9 (40.9) | 10 (50.0) | 11 (47.8) |
Allergy (fur, flower, and food)# | 0 | 20 (90.9) | 2 (10.0) | 7 (30.4) |
Positive Phadiatop® | 0 | 22(100) | 6 (30.0) | 2(8.7) |
Methacholine test positive | 0 | 22(100) | 11 (55.0) | 16 (69.7) |
Post FEV1%, predicted | 108.7 (101.2-112.5) | 104.5 (94.1–110.0) | 104.6 (98.6-115.9) | 90.2 (83.8-100.7)* |
Post FEV1 Z-score | 0.75 (-0.04-1.08) | 0.27 (-0.52-0.77) | 0.40 (-0.12-1.32) | -0.85 (-1.37- -0.15)** |
Post FVC %, predicted | 105.1 (98.6-110.1) | 103.0 (94.5-110.4) | 98.1 (92.8-111.2) | 94.9 (85.6–101.0)* |
Post FVC Z-score | 0.33 (-0.12- 0.69) | 0.20 (-0.48-0.85) | -0.17 (-0.52-0.77) | -0.41 (-1.24-0.06)** |
Post FEV1 /FVC | 0.90 (0.86–0.92) | 0.86 (0.85–0.89)* | 0.92 (0.86–0.94) | 0.83 (0.74–0.88)** |
Post FEV1 /FVC Z-score | 0.48 (-0.07-0.88) | -0.16 (-0.43-0.33)* | 0.69 (0.01–1.20) | -0.79 (-1.79-0.03)** |
FeNO, ppb | 10.7 (9.7–16.5) | 31.4 (11.6–49.2)* | 13.1 (10.5–19.4) | 14.7 (9.4–22.0) |
DLCO (% pred) | 87.0 (81.5–96.0) | 81.5 (75.0–91.0) | 78.5 (66.0-90.5)* | 69.5 (65.0–77.0)*** |
RV/TLC | 19.0 (17.0-22.5) | 18.5 (14.0–23.0) | 21.0 (18.0–23.0) | 20.0 (17.0–24.0) |
Perinatal period, n | ||||
BPD severity, (mild, moderate, severe), n | N/A | N/A | N/A | 9, 7, 7 |
Gestational age, weeks | 40.1 (39.4–40.6) | 39.9 (39.0–41.0) | 30.1 (29.3–30.7)** | 26.6 (26.3–28.2)** |
Birth weight, gram | 3457.5 (3245.0-3770.0) | 3444.5 (3024.0-3935.0) | 1470.0 (1132.5-1577.5)** | 962.0 (782.5-1137.5)** |
Apgar, 1 min | 9 (8–9) | 9 (9–9) | 8 (7–9) | 5 (4–8)** |
Apgar, 5 min | 10 (10–10) | 10 (9–10) | 9 (7–10)** | 7 (7–9)** |
Antenatal steroids | N/A | N/A | 12 (60.0) | 9 (39.1) |
Instillation of surfactant, | N/A | N/A | 2 (10.0) | 8 (34.8) |
Mechanical ventilation, days | N/A | N/A | 0 (0–0) | 6 (1–15) |
CPAP, days | -N/A (delete-) | -N/A(delete-) | 3.0 (2.0–5.0) | 38.5 (30.0–52.0) |
Supplemental O2, days | -N/A (delete-) | -N/A (delete-) | 3.0 (1.0-8.5) | 65.0 (58.0-83.5) |
Postnatal period | ||||
Inhaled corticosteroids | N/A | N/A | 0 | 15 (65.0) |